Orchestra Biomed Hldgs Inc OBIO

$5.72 -0.19 (-3.21%)

Valuation

Market cap
355,220,000
Revenue TTM
$33,480,000
Net income TTM
$-52,700,000
PE ratio
0.00
Forward PE
—
Profit margin
-157.41%
Debt to equity
1.80

Trading

Volume
204,800
Avg volume
330,520
Day's range
$5.71 – $5.87
Shares out
60,105,000
Stochastic %K
30%
Beta
0.52
Analysts
Strong Sell
Price target
$12.50

Price

Company profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodula...

Show more

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
215 862 5797
Website
https://www.orchestrabiomed.com
Address
150 Union Square Drive, New Hope, United States

Latest news

Stocktwits

Carl2233 Oct 12, 8:54 PM
$OBIO Brilliant business model!!
0 replies
JHisai Oct 7, 7:47 PM
$OBIO back to $5.0X maybe
0 replies
whiteyfulch Oct 5, 2:25 PM
$OBIO very interesting business model its like a biotech but with less risk with the Medtronic backing.
0 replies
focafoca99 Oct 1, 12:39 PM
$OBIO exceeds its BACKBEAT trial enrollment target, randomizing 330 patients versus the 316 goal.
0 replies
Carl2233 Oct 1, 12:16 AM
$OBIO I would like to add under $6 please
0 replies
JHisai Sep 29, 7:37 PM
$ALLO plz become like $IOVA or $OBIO
0 replies
ItsAllAboutBeingFirst Sep 22, 3:43 PM
$AIRS $ECOR $OBIO $OPEN
0 replies
ItsAllAboutBeingFirst Sep 22, 1:52 PM
$AIRS $ECOR $OBIO - keep making new highs
0 replies